



927 Carter Drive NE  
Atlanta, GA 30319

**FOR IMMEDIATE RELEASE**

**CONTACT:**

David E. Doolittle  
Public & Investor Relations  
404-840-1321  
david\_e\_doolittle@yahoo.com

Terence A. (Terry) Walts  
Transfusion & Transplantation Technologies LLC  
President, CEO  
678-860-3725  
tawalts@yahoo.com

**Transfusion & Transplantation Technologies Secures \$1.5 Million  
In New Financing, Including Major Grant From National Institutes of Health**

*NIH Grant Moves Aegis Automated Blood Bank Multianalyzer  
Closer to 510k Clinical Studies and Recognizes Commercialization Potential*

ATLANTA, GA – November 26, 2008 – Transfusion & Transplantation Technologies LLC (“3Ti”), developer of “next generation” automated blood bank multianalyzer technology for the pre-transfusion (immunohematology) diagnostics market, today announced the securing of over \$1.5 million in new financing from two sources. Over \$1.3 million of 3Ti’s latest financing was sourced through a National Institutes of Health (“NIH”) Small Business Technology Transfer Program (“STTR”) Phase II Competing Continuation grant award, which recognizes the commercial potential of a new technology. The remaining financing of approximately \$200,000 was sourced through private investors. 3Ti received official notice of the STTR award from the NIH in September.

“This significant grant is a tribute to 3Ti and, in particular, to Drs. John Roback and Christopher Hillyer of Emory University, who have worked tirelessly to make their vision for the future of blood bank automation a reality,” said Terry Walts, president and CEO of 3Ti. This grant serves as major recognition of the commercial potential of our *Aegis* blood bank multianalyzer”, said Walts, who also noted that the grant review panel is comprised largely of industry thought leaders who continued to be impressed with *Aegis*’ potential.

Drs. Hillyer and Roback are tenured Professor/Associate Professor at Emory and are co-founders of 3Ti and co-inventors of the *Aegis* technology. This relationship has been reviewed and approved by Emory’s conflict of interest committee.

**About the SBIR/STTR Program and Transfusion & Transplantation Technologies**

The STTR Program is an important NIH funding mechanism that involves small businesses in partnership with the nation’s premier nonprofit research institutions. The STTR Program involves three Phases. Phase I is the start-up phase designed to explore feasibility of an idea or technology and involves awards up to one year and in amounts up to \$100,000. 3Ti received its Phase I award for its *Aegis* analyzer in

September 2001 for the full \$100,000. Phase II is the expansion phase, designed to include consideration of a technology's commercialization potential. Phase II awards are only for successful Phase I recipients, for periods of up to two years, and typically in amounts of \$500,000 – \$750,000. 3Ti received its Phase II award in December 2002 for \$500,000. The Phase II Competing Continuation award funds successful Phase II work that requires federal regulatory approval, such as FDA 510k s, prior to commercialization. This particular NIH grant also puts 3Ti in a special class of recipients, given the rarity of this type award within the NIH SBIR/STTR program. According to the Small Business Administration's Web site (see Statistics, <http://www.sba.gov/SBIR/indexsbir-sttr.html>) and involving the most recent reported five years (2000-04):

- Of all SBIR/STTR grants awarded during this period—*only 8% were STTR awards.*
- Of all STTR grants awarded during this period—*only 24% were Phase II STTR awards.*

All STTR grants come with certain terms and conditions. In the case of 3Ti's latest grant, among other terms the \$1.3 million funding is to be spread out over three years and with Years II and III subject to the continued availability of NIH funds as well as satisfactory project progress.

#### **About Transfusion & Transplantation Technologies, LLC**

Founded in 2000 by two world renowned physician-scientists, Transfusion & Transplantation Technologies LLC is a medical device company developing “next generation” fully-automated blood bank multianalyzer technology for the pre-transfusion (immunohematology) diagnostics market worldwide. 3Ti's first product, the *Aegis* blood analyzer is being designed to perform traditional blood typing/grouping, antibody screening and cross-matching tests “*better, more efficiently and faster*” than competitive analyzers and/or manual testing today. In addition, it is anticipated that *Aegis*' technology based on fully automated flow cytometry and novel multifunctional flexible architecture will be capable of automating certain new tests as well as certain manual blood assays available but not capable of being automated on existing automated platforms to date (e.g., residual white blood cell counting). The company's mission is to become over time the *standard of care* in pre-transfusion (immunohematology) blood bank testing worldwide. For more information about Transfusion & Transplantation Technologies, contact David Doolittle at the number or email above, or the company directly.

###

#### **Forward-Looking Statements**

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's technologies, investment in product development, possible future financings or other activities and/or statements preceded by, followed by or that include the words “believes,” “could,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “projects,” “seeks,” “potential,” or similar expressions. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. All

forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.